- APGN Dashboard
- Financials
- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
CORRESP Filing
Apexigen (APGN) CORRESPCorrespondence with SEC
Filed: 20 Mar 23, 12:00am
March 20, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance,
100 F Street, N.E.
Washington, D.C. 20549-3628
Attention: |
| Josh Gorsky and Joe McCann |
|
|
|
Re: |
| Apexigen, Inc. File No. 333-269912 |
Acceleration Request
Requested Date: March 21, 2023
Requested Time: 4:05 p.m. Eastern Time,
or as soon thereafter as practicable
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Apexigen, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-1 (File No. 333-269912) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.
Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, Professional Corporation, by calling Lance Brady at (650) 565-3836.
Please direct any questions or comments regarding this acceleration request to Lance Brady at (650) 565-3836.
[Signature page follows]
Sincerely,
Apexigen, Inc.
/s/ Xiaodong Yang
Xiaodong Yang, M.D., Ph.D.
Chief Executive Officer
cc: | Francis Sarena, Apexigen, Inc. Michael E. Coke, Wilson Sonsini Goodrich & Rosati, Professional Corporation Lance Brady, Wilson Sonsini Goodrich & Rosati, Professional Corporation |